<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02952040</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0205</org_study_id>
    <nct_id>NCT02952040</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate</brief_title>
  <official_title>Pharmacokinetic Study of ASP1517 - Evaluation of the Effect of Lanthanum Carbonate Hydrate on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of lanthanum carbonate hydrate on the
      pharmacokinetics (PK) of ASP1517 in non-elderly healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP1517 in plasma: AUCINF</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1517 in plasma: AUC24h</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>AUC24h: Area under the concentration-time curve from the time of dosing to 24h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1517 in plasma: Cmax</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: AUClast</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>AUC last: Area under the concentration-time curve from the time of dosing to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: CL/F</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: t1/2</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: Lambda z</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>Lambda z: Terminal elimination rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: MRTinf</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>MRTinf: Mean residence time from the time of dosing extrapolated to time infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: tmax</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>tmax : Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: tlag</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>tlag: Time point prior to the time point corresponding to the first measurable (non-zero) concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in plasma: Vz/F</measure>
    <time_frame>Up to 72hr after each dosing</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase after single extra-vascular dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by incidence of adverse events</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by supine blood pressure</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by supine pulse rate</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by axillary body temperature</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Laboratory tests: Hematology</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Laboratory tests: Blood biochemistry</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by Laboratory tests: Urinalysis</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by 12-lead electrocardiogram</measure>
    <time_frame>Up to 7 days after drug dosing of period 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>ASP1517 alone period preceding group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of ASP1517 alone in period 1, then subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1517+lanthanum period preceding group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of ASP1517 with lanthanum carbonate hydrate in period 1, then subjects will receive a single oral dose of ASP1517 alone in period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1517</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>ASP1517+lanthanum period preceding group</arm_group_label>
    <arm_group_label>ASP1517 alone period preceding group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate hydrate</intervention_name>
    <description>Oral dose</description>
    <arm_group_label>ASP1517+lanthanum period preceding group</arm_group_label>
    <arm_group_label>ASP1517 alone period preceding group</arm_group_label>
    <other_name>Fosrenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight (at screening): ≥50.0 kg and &lt;80.0 kg

          -  Body-mass index (at screening): ≥17.6 and &lt;26.4 kg/m2 [Body-mass index = Body weight
             (kg)/(Height (m))2]

          -  Subject must agree to use contraception consisting of two established forms specified
             below starting at the time of informed consent and continuing throughout the treatment
             period and for 84 days after the last administration of ASP1517.

          -  Subject must agree not to donate sperm starting at the time of informed consent and
             continuing throughout 84 days after the last administration of ASP1517.

        Exclusion Criteria:

          -  Received or is scheduled to receive any investigational drugs in other clinical trials
             or post-marketing studies within 120 days before screening or during the period from
             screening to the hospital admission day of the Period 1.

          -  Received or is scheduled to receive medications (including over-the-counter drugs) or
             supplements within 7 days before the hospital admission day of the Period 1.

          -  Deviates from any of the normal range of blood pressure, pulse rate, body temperature
             and standard 12-lead electrocardiogram at screening or the hospital admission day of
             the Period 1.

          -  Meets any of the following criteria for laboratory tests at screening or the hospital
             admission day of the Period 1. Normal ranges of each test specified at the study site
             or the test/assay organization will be used as the normal ranges in this study.

          -  Concurrent or previous drug allergies.

          -  Development of (an) upper gastrointestinal symptom(s) within 7 days before the
             hospital admission day of the Period 1.

          -  Concurrent or previous hepatic disease, heart disease, respiratory disease, peritoneum
             inflammation.

          -  A history of abdominal surgery, digestive tract excision.

          -  Concurrent or previous renal disease, endocrine disease, cerebrovascular disorder,
             malignant tumor, retinal neovascular lesions.

          -  Previous use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) such
             as ASP1517 (FG-4592), YM311 (FG-2216), erythropoietin products or lanthanum carbonate
             hydrate.

          -  Excessive alcohol or smoking habit.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2016</study_first_submitted>
  <study_first_submitted_qc>October 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2016</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASP1517</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Drug-drug interaction</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

